‘Uncertainty’ Remains Over Supply of Key Cancer Drugs

<p>MONDAY, Jun 4 (HealthDay News) John Mahan, a 58-year-old
Nashville firefighter battling a gastrointestinal cancer, couldnt believe
what he was conference final July.
His alloy had usually told him that his hospital had run out of injectable
fluorouracil (5-FU), a general chemotherapy Mahan indispensable to keep his
tumor during bay.
My initial greeting was, youve got to be kidding, right? he
said.
Unfortunately, a news was all too real. Mahan was switched to another
drug, capecitabine. Taken in tablet form, it had a same anti-cancer
effectiveness as 5-FU though with some-more toilsome side effects.
It done me feel bad, weak, Mahan said, just run down, feeling tired
all of a time, detriment of appetite.
At a Monday news lecture during a annual assembly of a American Society
of Clinical Oncology (ASCO) in Chicago, Mahan spoke on interest of the
thousands of cancer patients who have been strike tough by a recent
nationwide shortages of generic, injectable cancer drugs.
The predi...